These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 29162215)

  • 1. Time course of the drug-drug interaction of acenocoumarol-miconazole.
    Lozano R; Frutos A
    Int J Clin Pharmacol Ther; 2018 Jan; 56(1):28-30. PubMed ID: 29162215
    [No Abstract]   [Full Text] [Related]  

  • 2. Miconazole oral gel enhances acenocoumarol anticoagulant activity: a report of three cases.
    Ortín M; Olalla JI; Muruzábal MJ; Peralta FG; Gutiérrez MA
    Ann Pharmacother; 1999 Feb; 33(2):175-7. PubMed ID: 10084413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of acenocoumarol during vaginal administration of miconazole.
    Lansdorp D; Bressers HP; Dekens-Konter JA; Meyboom RH
    Br J Clin Pharmacol; 1999 Feb; 47(2):225-6. PubMed ID: 10190660
    [No Abstract]   [Full Text] [Related]  

  • 4. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype.
    van Dijk KN; Plat AW; van Dijk AA; Piersma-Wichers M; de Vries-Bots AM; Slomp J; de Jong-van den Berg LT; Brouwers JR
    Thromb Haemost; 2004 Jan; 91(1):95-101. PubMed ID: 14691574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of OTC drug noscapine and acenocoumarol and phenprocoumon.
    Lokhorst B; Rolfes L; Jessurun NT
    Br J Clin Pharmacol; 2019 May; 85(5):1041-1043. PubMed ID: 30809820
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk prediction of drug-drug interaction potential of phenytoin and miconazole topical formulations.
    Li W; Wang Z; Wang X; Cao X; Bi C; Jiang L; Cui S; Liu Y
    Chem Biol Interact; 2021 Jul; 343():109498. PubMed ID: 33961833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.
    Schalekamp T; Brassé BP; Roijers JF; Chahid Y; van Geest-Daalderop JH; de Vries-Goldschmeding H; van Wijk EM; Egberts AC; de Boer A
    Clin Pharmacol Ther; 2006 Jul; 80(1):13-22. PubMed ID: 16815313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol.
    Sunkara G; Bigler H; Wang Y; Smith H; Prasad P; McLeod J; Ligueros-Saylan M
    Curr Med Res Opin; 2004 Jan; 20(1):41-8. PubMed ID: 14741071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period.
    Teichert M; van Schaik RH; Hofman A; Uitterlinden AG; de Smet PA; Stricker BH; Visser LE
    Clin Pharmacol Ther; 2009 Apr; 85(4):379-86. PubMed ID: 19225451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of acenocoumarol pharmacodynamics.
    Morin S; Bodin L; Loriot MA; Thijssen HH; Robert A; Strabach S; Verstuyft C; Tregouet DA; Dubert L; Laurent-Puig P; Funck-Brentano C; Jaillon P; Beaune PH; Becquemont L
    Clin Pharmacol Ther; 2004 May; 75(5):403-14. PubMed ID: 15116053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment.
    Gschwind L; Rollason V; Boehlen F; Rebsamen M; Combescure C; Grünenwald M; Matthey A; Bonnabry P; Dayer P; Desmeules JA
    Pharmacogenomics; 2013 May; 14(7):745-53. PubMed ID: 23651023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Plausible pharmacologic interaction between fosinopril and acenocoumarol].
    de Tomás ME; Sáez L; Beltrán S; Gato A
    Med Clin (Barc); 1997 May; 108(19):757. PubMed ID: 9324602
    [No Abstract]   [Full Text] [Related]  

  • 13. Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants.
    Visser LE; Penning-van Beest FJ; Kasbergen AA; De Smet PA; Vulto AG; Hofman A; Stricker BH
    Clin Pharmacol Ther; 2002 Jun; 71(6):496-502. PubMed ID: 12087353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nystatin and miconazole: pharmacological and clinical evidence regarding interactions with warfarin.
    Pemberton MN
    Oral Dis; 2016 Nov; 22(8):761-765. PubMed ID: 27416928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between topical miconazole and coumarins.
    Broos N; van Puijenbroek EP
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1171-2. PubMed ID: 20658342
    [No Abstract]   [Full Text] [Related]  

  • 16. Interaction of acenocoumarol and sitaxentan in pulmonary arterial hypertension.
    Pulido T; Sandoval J; Roquet I; Gutiérrez R; Rueda T; Peña H; Santos E; Miranda MT; Lupi E
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():14-8. PubMed ID: 19335742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prolonged diminished effect of coumarin derivatives after use of rifampicin].
    Harmsze AM; Deneer VH; Wiltink EH
    Ned Tijdschr Geneeskd; 2007 Sep; 151(35):1945-9. PubMed ID: 17907547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-drug interactions with metronidazole and itraconazole in patients using acenocoumarol.
    Becker ML; van Uden RCAE; Giezen TJ; Meijer K; Houtenbos I; van den Bemt PMLA
    Eur J Clin Pharmacol; 2020 Oct; 76(10):1457-1464. PubMed ID: 32524154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acenocoumarol and 6-mercaptopurine: an important drug interaction.
    Fernández MA; Regadera A; Aznar J
    Haematologica; 1999 Jul; 84(7):664-5. PubMed ID: 10406922
    [No Abstract]   [Full Text] [Related]  

  • 20. Interaction between cyclosporine and acenocoumarol in a patient with nephrotic syndrome.
    Borrás-Blasco J; Enriquez R; Navarro-Ruiz A; Martinez-Ramirez M; Cabezuelo JB; Gonzalez-Delgado M
    Clin Nephrol; 2001 Apr; 55(4):338-40. PubMed ID: 11334326
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.